# OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

> **NCT06967519** · PHASE4 · RECRUITING · sponsor: **Yale University** · enrollment: 380 (estimated)

## Conditions studied

- Malaria
- Hiv

## Interventions

- **DRUG:** Artemether-lumefantrine (AL)
- **DRUG:** artesunate-amodiaquine (AS-AQ)

## Key facts

- **NCT ID:** NCT06967519
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06967519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06967519, "OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06967519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*